BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Jiang X, Zhao Y, Xu Y. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis. J Viral Hepat 2021;28:177-85. [PMID: 32961624 DOI: 10.1111/jvh.13409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Jeelan Basha N, Basavarajaiah SM, Shyamsunder K. Therapeutic potential of pyrrole and pyrrolidine analogs: an update. Mol Divers. [DOI: 10.1007/s11030-022-10387-8] [Reference Citation Analysis]
2 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
3 Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R, Coppola N. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Viruses 2021;13:432. [PMID: 33800289 DOI: 10.3390/v13030432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]